23:36:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaLarge Cap Helsinki
SektorHälsovård
IndustriMedicinteknik
Revenio är verksamma inom medicinteknik. Inom koncernen återfinns forskning och utveckling av tryckmätningsteknik som används vid behandling av ett flertal sjukdomar som glaukom, osteoporos, hudcancer samt astma. Verksamhet innehas på global nivå och drivs via flertalet dotterbolag med vardera affärsinriktning. Bolagets huvudkontor ligger i Vantaa.

Kalender

2022-10-27 Kvartalsrapport 2022-Q3
2022-08-04 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-11 Ordinarie utdelning REG1V 0.34 EUR
2022-04-08 Årsstämma 2022
2022-02-10 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-05 Kvartalsrapport 2021-Q2
2021-04-23 Kvartalsrapport 2021-Q1
2021-03-18 Ordinarie utdelning REG1V 0.32 EUR
2021-03-17 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-06 Kvartalsrapport 2020-Q2
2020-06-09 Ordinarie utdelning REG1V 0.30 EUR
2020-06-08 Årsstämma 2020
2020-04-22 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-04-16 Kvartalsrapport 2019-Q1
2019-03-21 Ordinarie utdelning REG1V 0.28 EUR
2019-03-20 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-06 Kvartalsrapport 2018-Q2
2018-04-20 Kvartalsrapport 2018-Q1
2018-03-21 Ordinarie utdelning REG1V 0.78 EUR
2018-03-20 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-07 Kvartalsrapport 2017-Q2
2017-05-22 Årsstämma 2017
2017-04-20 Kvartalsrapport 2017-Q1
2017-03-23 Ordinarie utdelning REG1V 0.74 EUR
2017-02-16 Bokslutskommuniké 2016
2016-10-31 Kvartalsrapport 2016-Q3
2016-08-08 Kvartalsrapport 2016-Q2
2016-04-25 Kvartalsrapport 2016-Q1
2016-03-16 Ordinarie utdelning REG1V 0.70 EUR
2016-03-15 Årsstämma 2016
2016-02-15 Bokslutskommuniké 2015
2015-10-27 Kvartalsrapport 2015-Q3
2015-08-10 Kvartalsrapport 2015-Q2
2015-04-24 Kvartalsrapport 2015-Q1
2015-03-20 Ordinarie utdelning REG1V 0.45 EUR
2015-03-19 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-10-21 Kvartalsrapport 2014-Q3
2014-08-04 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-03-21 Ordinarie utdelning REG1V 0.30 EUR
2014-03-20 Årsstämma 2014
2014-02-12 Bokslutskommuniké 2013
2013-12-11 Bonusutdelning REG1V 0.3
2013-12-09 Extra Bolagsstämma 2013
2013-10-22 Kvartalsrapport 2013-Q3
2013-08-28 Kapitalmarknadsdag 2013
2013-08-05 Kvartalsrapport 2013-Q2
2013-08-02 Bonusutdelning REG1V 0.12
2013-04-19 Kvartalsrapport 2013-Q1
2013-03-28 Split REG1V 10:1
2013-03-22 Ordinarie utdelning REG1V 0.02 EUR
2013-03-21 Årsstämma 2013
2013-02-08 Bokslutskommuniké 2012
2012-10-19 Kvartalsrapport 2012-Q3
2012-08-06 Kvartalsrapport 2012-Q2
2012-04-19 Kvartalsrapport 2012-Q1
2012-03-29 Ordinarie utdelning REG1V 0.02 EUR
2012-03-28 Årsstämma 2012
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-08 Kvartalsrapport 2011-Q2
2011-04-01 Ordinarie utdelning REG1V 0.02 EUR
2010-04-09 Ordinarie utdelning REG1V 0.01 EUR
2009-04-16 Ordinarie utdelning REG1V 0.02 EUR
2008-04-03 Ordinarie utdelning REG1V 0.04 EUR
2007-04-09 Ordinarie utdelning REG1V 0.01 EUR
2006-03-31 Ordinarie utdelning REG1V 0.00 EUR
2005-04-01 Ordinarie utdelning REG1V 0.00 EUR
2004-03-29 Ordinarie utdelning REG1V 0.00 EUR
2003-03-24 Ordinarie utdelning REG1V 0.00 EUR
2002-04-15 Ordinarie utdelning REG1V 0.00 EUR
2022-04-28 08:00:00

Revenio Group Corporation, Stock exchange release, April 28, 2022 at 9.00 a.m. (EEST)

Revenio Group Corporation: Interim report January 1 - March 31, 2022

Strong start for the year driven by Europe and US

The figures in parentheses refer to the corresponding period in the previous year unless otherwise stated.

January – March 2022

  • Net sales totaled EUR 20.2 (16.8) million, showing an increase of 20.5%
  • The currency-adjusted growth of net sales in January–March was 17.1%
  • Operating profit was EUR 5.6 (4.6) million, representing 27.5% of net sales and growth of 20.6%
  • The EUR 0.6 million non-recurring costs of the Oculo acquisition had a negative impact on the operating profit for the comparison period. Compared to the adjusted operating profit for the comparison period, the operating profit increased by 6.0%.
  • EBITDA was EUR 6.4 (5.3) million, up 21.0%
  • Cash flow from operations totaled EUR -0.2 (0.6) million. Cash flow from operations was affected by the payout of annual short and long-term incentives.
  • Undiluted earnings per share came to EUR 0.176 (0.141)
  • The Annual General Meeting was held on April 8, 2022 after the review period. Dividend was set at EUR 0.34 and paid on April 21, 2022.

Key consolidated figures, EUR million


1-3/20221-3/2021Change-%1-12/2021
Net sales20.216.820.578.8
Currency-adjusted sales19.316.517.179.6
Gross margin14.712.022.155.8
Gross margin - %72.671.71.070.8
EBITDA6.45.321.025.7
EBITDA-%31.731.50.132.7
Adjusted EBITDA6.45.98.026.4
Adjusted EBITDA - %31.735.3-3.633.5
Operating profit, EBIT5.64.620.622.1
Operating profit-%, EBIT27.527.50.028.1
Adjusted Operating profit, EBIT5.65.26.023.4
Adjusted Operating profit-%, EBIT27.531.3-3.829.7
Return on investment-%, ROI5.65.20.422.4
Return on equity-%, ROE5.85.60.223.4
Undiluted earnings per share0.1760.14124.80.652






Mar 31, 2022Mar 31, 2021Change, %-pointDec 31, 2021
Equity ratio-%67.460.37.163.0
Net gearing-%0.86.5-5.7-1.0

Financial guidance for 2022

Revenio Group’s exchange rate-adjusted net sales are estimated to grow strongly from the previous year and profitability, excluding non-recurring items, is estimated to remain at a good level.

President and CEO Jouni Toijala comments on the first quarter of 2022:

“The first quarter performance from our team was excellent. Our net sales increased by 20.5% to EUR 20.2 million, and the operating profit was EUR 5.6 million or 27.5% of net sales. It is important to note that the adjusted comparison period does not include any development costs for the software solutions. Both of our product groups saw good demand, with very strong growth in sales of retinal imaging devices. The very strong sales growth was driven by the competitive positioning of devices, and our continued success in gaining market share. In the coming years, we believe our retinal imaging devices will grow faster than our intraocular pressure measurement devices, as we have previously guided.

During the first quarter demand was strong in all our key markets. In the US and in Europe the sales volume grew, particularly in Italy, the United Kingdom, Sweden, and the Netherlands. The COVID-19 situation in Asia is creating some challenges and making it difficult to predict the future.

Our software solutions are playing an increasingly important role in eye care pathways. We launched iCare ILLUME, a software solution for the care pathway of diabetic retinopathy after the reporting period. Patient images taken with the iCare DRSplus fundus imaging system are automatically transferred to our iCare ILLUME software cloud service. An AI-based report will be generated instantly. The iCare ILLUME can be used for other eye diseases in the future. This allows us to utilize the high-quality data generated by the iCare fundus imaging devices even more extensively as support for clinical decision-making.

Our goal is to continuously develop Revenio’s strong product portfolio by bringing new product innovations and software solutions to the market. We aim to further increase our research and product development investments in 2022, as well as in 2023.

Russia’s recent invasion of Ukraine has shocked the western world, including us at Revenio. This has resulted in a fundamental change in the European security situation. We have stopped all business with Russia and Belarus. Revenio’s operations in Russia have been minor, accounting for less than two per cent of net sales.

During the first quarter of the year our production chain for imaging devices faced challenges due to COVID-19-related employee absences. As a result, orders worth more than half a million euros could not be delivered in the first quarter. Production and deliveries of imaging devices have, however, normalized in April. Although the continuing global component shortages did not impact our deliveries during the first quarter, there remains a risk that component availability and related price volatility may pose challenges later in the year. In addition, regional lockdowns caused by the COVID-19 pandemic in China may affect component availability.

Despite the geopolitical and global economic uncertainties, we start the next quarter confidently. I wish to give special thanks to our entire organization, who have shown extraordinary resilience and operational capability during an exceptional start to the year.”

FINANCIAL REVIEW

INTERIM REPORT JANUARY 1–MARCH 31, 2022, TABLES

Accounting policies applied in the preparation of the interim report
This interim report is not prepared in accordance with IAS 34. Revenio Group adheres to half-year reporting
in accordance with the Securities Markets Act and, for the first three and nine months of the year, publishes
interim reports to present key information on the Group’s financial performance. The financial figures presented in this interim report are unaudited. The financial statement bulletin and the interim report for 1–6/2022 are drawn up in accordance with IAS 34 Interim Financial Reporting.

Consolidated comprehensive income statement (EUR million)


1-3/20221-3/20211-12/2021
NET SALES20.216.878.8
Other operating income0.00.00.9
Materials and services-5.5-4.8-23.0
Employee benefits-4.8-3.1-16.4
Depreciation, amortization, and
impairment
-0.8-0.7-3.6
Other operating expenses-3.5-3.7-14.5
OPERATING PROFIT5.64.622.1
Financial income and expenses (net)0.30.10.0
PROFIT BEFORE TAXES5.84.722.1
Income taxes-1.2-1.0-4.8
NET PROFIT4.73.717.3
Other comprehensive income items0.70.20.1
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD5.33.917.5
Earnings per share, undiluted, EUR0.1760.1410.652
Earnings per share, diluted, EUR0.1760.1410.652

Consolidated balance sheet (EUR million)


Mar 31, 2022Mar 31, 2021Dec 31, 2021
ASSETS


NON-CURRENT ASSETS


Tangible assets3.02.02.6
Goodwill60.350.459.8
Intangible assets17.816.618.2
Right-of-use assets1.50.81.7
Other receivables0.60.10.2
Deferred tax assets0.00.00.0
TOTAL NON-CURRENT ASSETS83.270.082.4
CURRENT ASSETS


Inventories6.05.56.4
Trade and other receivables9.77.99.2
Deferred tax assets1.71.41.3
Cash and cash equivalents22.621.925.2
TOTAL CURRENT ASSETS40.036.642.2
TOTAL ASSETS123.1106.6124.6
SHAREHOLDERS’ EQUITY AND
LIABILITIES



SHAREHOLDERS' EQUITY


Share capital5.35.35.3
Fair value reserve0.30.30.3
Reserve for invested unrestricted capital52.452.552.6
Other reserves0.30.30.3
Retained earnings/loss26.08.222.1
Translationdifference0.6-0.10.0
Own shares held by the company-2.0-2.2-2.1
TOTAL SHAREHOLDERS' EQUITY82.964.378.4
LIABILITIES


NON-CURRENT LIABILITIES


Deferred tax liabilities3.53.93.6
Financial liabilities18.222.40.8
Lease liabilities0.80.30.9
TOTAL LONG-TERM LIABILITIES22.626.55.3
CURRENT LIABILITIES


Trade and other payables12.111.416.9
Provisions0.50.30.5
Financial liabilities4.33.622.7
Lease liabilities0.70.50.8
TOTAL CURRENT LIABILITIES17.615.840.9
TOTAL LIABILITIES40.142.446.2
TOTAL SHAREHOLDERS' EQUITY


AND TOTAL LIABILITIES123.1106.6124.6


Consolidated statement of changes in equity (EUR million)



Reserve for






invested





ShareunrestrictedOtherRetainedTranslationOwnTotal

capitalequityReservesEarningsdifferencesharesEquity
Balance 1 Jan 20225.352.60.622.10.0-2.178.4
Dividend distribution0.00.00.00.00.00.00.0
Disposal and purchase of own shares0.0-0.20.00.00.00.20.0
Other direct entries to retained earnings0.00.00.0-0.80.00.0-0.8
Used option rights0.00.00.00.00.00.00.0
Total comprehensive income0.00.00.04.70.70.05.3
Balance 31 March 20225.352.40.626.00.6-2.082.9










Reserve for






invested





ShareunrestrictedOtherRetainedTranslationOwnTotal

capitalequityReservesEarningsdifferencesharesEquity
Balance 1 Jan 20215.352.50.614.0-0.3-2.369.7
Dividend distribution0.00.00.0-8.50.00.0-8.5
Disposal and purchase of own shares0.0-0.20.00.00.00.20.0
Other direct entries to retained earnings0.00.00.0-1.10.00.0-1.1
Used option rights0.00.20.00.00.00.00.2
Total comprehensive income0.00.00.03.70.20.03.9
Balance 31 March 20215.352.50.68.2-0.1-2.264.3

Consolidated cash flow statement (EUR million)


1-3/20221-3/20211-12/2021
CASH FLOW FROM OPERATIONS


Profit for the period4.73.717.3
Adjustments:



Depreciation, amortization, and
impairment
0.80.73.6

Other non-cash items0.7-0.70.6

Interest and other financial expenses0.10.10.4

Interest income and other financial income-0.4-0.1-0.4

Taxes1.21.04.8

Other adjustments-0.80.0-1.1
Change in working capital:



Changes in sales and other receivables-0.51.40.4

Changes in current assets0.4-0.7-1.5

Changes in trade and other payables-4.2-1.92.2
Change in working capital, total-4.3-1.21.1
Interest paid-0.1-0.1-0.2
Interest received0.00.00.0
Taxes paid-2.1-2.7-4.5
NET CASH FLOW FROM OPERATING ACTIVITIES-0.20.621.5
CASH FLOW FROM INVESTING ACTIVITIES


Acquisitions of subsidiaries less cash and cash equivalents at acquisition time0.00.0-11.3
Purchase of tangible assets-0.6-0.2-1.2
Purchase of intangible assets-0.6-0.1-1.0
Purchase of other investments-0.40.00.0
NET CASH FLOW FROM INVESTING ACTIVITIES-1.6-0.3-13.5
CASH FLOW FROM FINANCING ACTIVITIES


Repayments of loans-1.1-1.1-3.2
Dividends paid0.0-6.6-8.5
Share subscription through exercised options0.00.20.3
Acquisition of own shares0.00.00.0
Payments of lease agreement liabilities-0.2-0.2-0.7
NET CASH FLOW FROM FINANCING ACTIVITIES-1.3-7.6-12.1
Net change in cash and credit accounts-3.1-7.2-4.2
Cash and cash equivalents at beginning of period25.228.928.9
Effect of exchange rates0.40.20.5
Cash and cash equivalents at end of period22.621.925.2

Key consolidated figures, EUR million


1-3/20221-3/20211-12/2021
Net sales20.216.878.8
Ebitda6.45.325.7
Ebitda-%31.731.532.7
Operating profit5.64.622.1
Operating profit-%27.527.528.1
Profit before taxes5.84.722.1
Profit before taxes, %28.828.128.1
Net result for the period4.73.717.3
Net result for the period, %23.122.322.0
Gross capital expenditure1.60.215.7
Gross capital expenditure-% from net sales7.81.119.9
R&D costs1.61.36.5
R&D costs-% from net sales8.08.08.3
Net gearing-%0.86.5-1.0
Equity ratio-%67.460.363.0
Return on investment-% (ROI)5.65.222.4
Return on equity-% (ROE)5.85.623.4
Undiluted earnings per share, EUR0.1760.1410.652
Diluted Earnings per share, EUR0.1760.1410.652
Equity per share, EUR3.112.412.94
Average no. of employees184144167
Cash flow from operating activities-0.20.621.5
Cash flow from investing activities-1.6-0.3-13.5
Net cash used in financing activities-1.3-7.6-12.1
Total cash flow-3.1-7.2-4.2

Alternative growth indicators used in financial reporting

Revenio has adopted the guidelines of the European Securities and Market Authority (ESMA) on Alternative Performance Measures. In addition to the IFRS-based key figures, the company will publish certain other generally used key figures that may, as a rule, be derived from the income statement and balance sheet. The calculation of these figures is presented below. According to the company’s view, these key figures supplement the income statement and balance sheet, providing a better picture of the company’s financial performance and position.

Revenio Group’s net sales are strongly affected by fluctuations in the exchange rate between the euro and the US dollar. As an alternative growth indicator, we also present our net sales with the exchange rate effect eliminated.

Alternative growth indicator (EUR thousand)1-3/2022
Reported net sales20,193
Effect of exchange rates on net sales-860
Net sales adjusted by the effect of exchange rates19,333
Growth in net sales, adjusted by the effect of exchange rates17.1 %
Reported net sales growth20.5 %
Difference, % points-3.4 %

Alternative profitability indicator EBITDA (EUR thousand)
EBITDA = Operating profit + depreciation + impairment

As an alternative growth indicator, the company also presents profitability as an operating margin (EBITDA) key figure.

Alternative profitability indicator (EBITDA) (EUR thousand)1-3/20221-3/20211-12/2021
Operating profit, EBIT5,5614,61322,103
Depreciation, amortization, and impairment8316703,620
EBITDA6,3925,28325,722


Operating profit adjusted by non-recurring costs (EUR thousand)1-3/20221-3/20211-12/2021
Operating profit, EBIT5,5614,61322,103
Cutica related impaiment00628
Non-recurring costs of the acquisition0634678
Adjusted operating profit, EBIT5,5615,24723,409


EBITDA adjusted by non-recurring acquisition costs (EUR thousand)1-3/20221-3/20211-12/2021
EBITDA6,3925,28325,722
Non-recurring costs of the acquisition0634678
Adjusted operating profit, EBITDA6,3925,91726,401


Formulas

EBITDA=
EBITDA = Operating profit + amortization + impairment
Gross margin=
Sales revenue – variable costs
Earnings per share=
Net profit for the period (attributable to the parent company’s shareholders)
Average number of shares during the period – own shares purchased
Profit before taxes=
Operating profit + financial income – financial expenses
Equity ratio, %=100 xShareholders’ equity on the balance sheet + non-controlling interest
Balance sheet total – advance payments received
Net gearing, %=100 xInterest-bearing debt – cash and cash equivalents
Total equity
Return on equity (ROE), %=100 xProfit for the period
Shareholders’ equity + non-controlling interest
Return on investment (ROI), %=100 xProfit before taxes + interest and other financial expenses
Balance sheet total – non-interest-bearing debt
Equity per share=
Equity attributable to shareholders
Number of shares at the end of the period

General statement
This report contains certain statements that are estimates based on the management’s best knowledge at the time they were made. For this reason, they involve a certain amount of inherent risk and uncertainty. The estimates may change in the event of significant changes in the general economic conditions.

Revenio Group Corporation
Board of Directors

Audiocast and conference call
President & CEO Jouni Toijala and CFO Robin Pulkkinen will present the Q1/2022 results in an audiocast and a conference call for analysts and investors at 3.00 p.m. (EEST) on the same day.

The audiocast can be followed at https://revenio.videosync.fi/results-q1-2022.

Conference call dial in numbers:
Finland: +358 9 8171 0310
Sweden: +46 8 5664 2651
United Kingdom: +44 33 3300 0804
United States: +1 63 1913 1422

PIN: 77956089#

For further information, please contact
Jouni Toijala, President & CEO, tel. +358 50 484 0085
jouni.toijala@revenio.fi

Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.